{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nelson CS"],"funding":["NICHD NIH HHS","NIAID NIH HHS","HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","NIGMS NIH HHS","NIH HHS","Division of Intramural Research, National Institute of Allergy and Infectious Diseases"],"pagination":["6267-6272"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6004431"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["115(24)"],"pubmed_abstract":["Human cytomegalovirus (HCMV) is the most common congenital infection worldwide, frequently causing hearing loss and brain damage in afflicted infants. A vaccine to prevent maternal acquisition of HCMV during pregnancy is necessary to reduce the incidence of infant disease. The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful HCMV vaccine tested to date, demonstrating ∼50% efficacy in preventing HCMV acquisition in multiple phase 2 trials. However, the mechanism of vaccine protection remains unknown. Plasma from 33 postpartum women gB/MF59 vaccinees at peak immunogenicity was tested for gB epitope specificity as well as neutralizing and nonneutralizing anti-HCMV effector functions and compared with an HCMV-seropositive cohort. gB/MF59 vaccination elicited "],"journal":["Proceedings of the National Academy of Sciences of the United States of America"],"pubmed_title":["HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions."],"pmcid":["PMC6004431"],"funding_grant_id":["K01 OD024877","R21AI136556","F30 HD089577","F30HD089577","P30 AI064518","DP2 HD075699","T32 GM007171","R21 AI136556","DP2HD075699"],"pubmed_authors":["Huffman T","Xie G","Pass RF","Permar SR","Jenks JA","Pollara J","Vandergrift N","Nelson CS","Cisneros de la Rosa E"],"additional_accession":[]},"is_claimable":false,"name":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.","description":"Human cytomegalovirus (HCMV) is the most common congenital infection worldwide, frequently causing hearing loss and brain damage in afflicted infants. A vaccine to prevent maternal acquisition of HCMV during pregnancy is necessary to reduce the incidence of infant disease. The glycoprotein B (gB) + MF59 adjuvant subunit vaccine platform is the most successful HCMV vaccine tested to date, demonstrating ∼50% efficacy in preventing HCMV acquisition in multiple phase 2 trials. However, the mechanism of vaccine protection remains unknown. Plasma from 33 postpartum women gB/MF59 vaccinees at peak immunogenicity was tested for gB epitope specificity as well as neutralizing and nonneutralizing anti-HCMV effector functions and compared with an HCMV-seropositive cohort. gB/MF59 vaccination elicited ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2026-05-06T06:45:31.135Z","creation":"2019-03-27T00:10:57Z"},"accession":"S-EPMC6004431","cross_references":{"pubmed":["29712861"],"doi":["10.1073/pnas.1800177115"]}}